Amal Mehta, MD
Rheumatology · Hemet, CANPI 1639374549
Payments from drug & device makers
Across 704 payments — averaging $4918.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$1.9M
- Eli Lilly$366K
- GSK$351K
- Astrazeneca UK Limited$316K
- AbbVie$207K
- Gilead$195K
- plus $142K from 28 others
Across 1 payment — averaging $104.58 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$105
What the payments were for
- Speaking & faculty fees$4,50029%
- Travel & lodging$130%
- Food & beverage$11,03870%
- Education$1261%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 88 | $1,885,831 |
| Eli Lilly | 5 | $366,160 |
| GSK | 50 | $350,592 |
| Astrazeneca UK Limited | 15 | $315,744 |
| AbbVie | 207 | $207,174 |
| Gilead | 43 | $194,540 |
| Janssen Research & Development, LLC | 15 | $135,092 |
| Hexal AG | 1 | $1,610 |
| UCB, Inc. | 62 | $1,371 |
| Pfizer | 46 | $716 |
| AstraZeneca(2 entities) | 39 | $675 |
| Novartis | 34 | $604 |
| Johnson & Johnson(2 entities) | 29 | $590 |
| Lilly USA, LLC | 20 | $390 |
| E.r. Squibb & Sons, L.L.C. | 14 | $332 |
| Galderma Laboratories, L.p. | 1 | $128 |
| Abbott | 2 | $127 |
| Sanofi | 3 | $92 |
| Genentech USA, Inc. | 5 | $86 |
| Aurinia Pharma U.S., Inc. | 4 | $82 |
| Boehringer Ingelheim | 3 | $73 |
| ANI Pharmaceuticals, Inc. | 3 | $66 |
| Mallinckrodt Hospital Products Inc. | 3 | $60 |
| Fidia Pharma USA Inc. | 2 | $30 |
| Sandoz | 1 | $23 |
| Tonix Medicines, Inc. | 1 | $22 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $21 |
| Radius Health, Inc. | 1 | $21 |
| Ferring Pharmaceuticals Inc. | 1 | $20 |
| Scilex Pharmaceuticals Inc. | 1 | $18 |
| Alvogen Inc | 1 | $16 |
| Sobi, Inc | 1 | $15 |
| Octapharma USA, Inc. | 1 | $14 |
| Kyowa Kirin, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,462,348 in reported general payments places this provider in the 95th percentile of 808 rheumatology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 43 | $357,131 |
| RinvoqUpadacitinib | 38 | $283,774 |
| Orencia ClickjectAbatacept | 44 | $275,863 |
| Enbrel SureclickEtanercept | 30 | $216,559 |
| ProliaDenosumab | 130 | $212,593 |
| Xeljanz XrTofacitinib Citrate | 13 | $108,698 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 13 | $100,527 |
| SaphneloAnifrolumab-Fnia | 19 | $96,599 |
| RemicadeInfliximab | 12 | $57,965 |
| Evenity (2 Syringes)Romosozumab-Aqqg | 20 | $46,797 |
| ForteoTeriparatide | 11 | $46,379 |
| BenlystaBelimumab | 15 | $35,867 |
| Teriparatide | 15 | $29,559 |
| Hydroxychloroquine Sulfate | 385 | $19,641 |
| MethotrexateMethotrexate Sodium | 341 | $12,407 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq | $207,174 | $283,77438 claims |
| AmgenProlia, Evenity (2 Syringes) | $1,885,831 | $259,390150 claims |
| AstraZenecaSaphnelo | $675 | $96,59919 claims |
| Johnson & JohnsonRemicade | $590 | $57,96512 claims |
| Lilly USA, LLCForteo | $390 | $46,37911 claims |
| GSKBenlysta | $350,592 | $35,86715 claims |
| Alvogen IncTeriparatide | $16 | $29,55915 claims |
| Scilex Pharmaceuticals Inc.Colchicine | $18 | $55414 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 808 rheumatology providers in California.
Other rheumatology in Hemet
- Samy MetyasCovina$12.9M
- Christine ThaiHuntington Beach$8.5M
- Tien-I SuWhittier$8.4M
- Eric LeeUpland$6.9M
- Orrin TroumSanta Monica$6.9M
- Shirley PangFullerton$5.7M
- William RobinsonStanford$5.1M
- Dan laTujunga$5.1M
- Christina Charles-SchoemanLos Angeles$4.8M
- Suneet GrewalWest Hollywood$3.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.